CytomX Therapeutics, Inc. (CTMX) - Q2 2025 Filing Summary
Business Context and Reporting Period
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing conditionally activated biologics using its proprietary PROBODY® platform. This summary covers the quarterly period ended June 30, 2025. The company operates as a single segment and relies on collaboration agreements and equity financing for revenue and liquidity, as it has no approved products for commercial sale.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $18.7 million | $69.6 million | $66.6 million |
| Net Income (Loss) | $(0.2) million | $23.4 million | $7.3 million |
| Operating Expenses | $20.0 million | $48.2 million | $63.4 million |
| Cash & Short-Term Investments | $158.1 million (as of June 30, 2025) | ||
| Accumulated Deficit | $(668.2) million (as of June 30, 2025) | ||
| Deferred Revenue | $32.3 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Recognition: Q2 2025 revenue decreased $6.5 million compared to Q2 2024, primarily due to the completion of performance obligations under the Bristol Myers Squibb (BMS) and Amgen agreements. However, YTD 2025 revenue increased $3.0 million compared to YTD 2024, driven by an $8.4 million cumulative adjustment from the Amgen agreement termination and higher completion percentages on BMS targets.
- Profitability: The company reported a net loss of $0.2 million for Q2 2025, contrasting with a net loss of $6.5 million in Q2 2024. YTD 2025 net income was $23.4 million, significantly higher than the $7.3 million in YTD 2024, largely due to the aforementioned revenue adjustments and reduced operating expenses.
- Operating Expenses: Total operating expenses decreased $15.0 million YTD 2025 compared to YTD 2024. This reduction is attributed to a one-time $5.0 million royalty payment to ImmunoGen (AbbVie) in Q2 2024, the termination of the CX-904 program, and cost savings from a workforce reduction of approximately 40% completed in Q1 2025.
- Capital Raise: In May 2025, the company completed an underwritten public offering of 76.9 million shares at $1.30 per share, raising net proceeds of approximately $93.4 million.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing capital resources ($158.1 million in cash and investments) to fund operations into the second quarter of 2027. Additional capital will be required thereafter.
- Clinical Pipeline:
- CX-2051 (EpCAM ADC): Phase 1 dose escalation reached level 7. Interim data showed a 28% confirmed partial response rate in colorectal cancer patients. Dose expansion cohorts initiated; Phase 2 study planned for H1 2026.
- CX-801 (IFNα2b): Phase 1 dose escalation ongoing in melanoma. Combination study with KEYTRUDA® initiated in May 2025.
- Program Termination: The CX-904 program (partnered with Amgen) was terminated in March 2025 based on clinical observations and pipeline prioritization.
- Collaboration Updates:
- Amgen: License for EGFR Product terminated; remaining deferred revenue recognized. Collaboration continues on a preclinical TCE.
- BMS: Research term concluded in Q2 2025; remaining deferred revenue recognized. Two preclinical programs remain.
- Astellas: Achieved GLP toxicology milestone for a second target in Q1 2025, triggering a $5.0 million payment.
- Moderna: Activities paused due to partner budget considerations; revenue recognition expected primarily in 2026-2027.
- Risks: Key risks include the uncertainty of clinical trial outcomes, reliance on third-party manufacturers (including in China), potential inability to raise additional capital on favorable terms, and the impact of the ongoing California tax assessment dispute ($4.2 million liability recorded).
Investor Verification Checklist
- Verify the sustainability of revenue streams given the completion of major performance obligations with BMS and Amgen in Q2 2025.
- Confirm the timeline and budget for the planned Phase 2 study of CX-2051 in H1 2026.
- Monitor the status of the California Franchise Tax Board assessment and potential impact on future tax liabilities.
- Assess the impact of the Moderna collaboration pause on future deferred revenue recognition schedules.
- Review the company's cash burn rate post-restructuring to validate the runway into Q2 2027.